ODYSSEY ALTERNATIVE ( NCT@ ) evaluates efficacy and safety of alirocumab , a fully human proprotein convertase subtilisin/kexin type @ monoclonal antibody , in patients with well-documented statin intolerance and moderate to very high cardiovascular risk .